---
title: "Skyrizi (risankizumab-rzaa) in plaque psoriasis: Dosing and administration questions"
description: "Dosing and administration questions on Skyrizi (risankizumab-rzaa) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Switching, Dosing, and Administration. Questions: What happens when patients switch to Skyrizi from Stelara (ustekinumab)? Does switching to Skyrizi help Humira (adalimumab) patients who did not reach PASI 90? Does the Skyrizi dose depend on body weight? What is the Skyrizi dosage for plaque psoriasis? 3 further questions follow. 7 questions quoted from 5 sources."
canonical: "https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/dosing-and-administration"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Skyrizi (risankizumab-rzaa) in plaque psoriasis: Dosing and administration questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Skyrizi](https://www.skyrizihcp.com/prescribinginfo)

Dosing and administration questions that apply to every indication of Skyrizi are on [Skyrizi (risankizumab-rzaa), all indications: Dosing and administration](https://www.evicenter.com/medical-information/skyrizi/dosing-and-administration).

## Switching

<a id="skyrizi-switch-from-stelara"></a>

### What happens when patients switch to Skyrizi from Stelara (ustekinumab)?

Applies to: Adults with moderate-to-severe plaque psoriasis

> “Following completion of the RCT period, patients on blinded STELARA were switched to open-label SKYRIZI.<sup>4</sup>”

Source: [SKYRIZI: STELARA® to SKYRIZI® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-stelara#:~:text=Following%20completion%20of%20the%20RCT,STELARA%20were%20switched%20to%20open%2Dlabel)

> “73% OF PATIENTS ACHIEVED PASI 90 AFTER 1 DOSE (12 WEEKS) OF SKYRIZI<sup>3,4</sup>
>
> INTEGRATED RESULTS FROM ULTIMMA-1 & -2 PATIENTS (LOCF)”

Source: [SKYRIZI: STELARA® to SKYRIZI® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-stelara#:~:text=73%25%20OF%20PATIENTS%20ACHIEVED%20PASI,ULTIMMA%2D1%20%26%20%2D2%20PATIENTS%20%28LOCF%29)

> “The randomized controlled trial data shown here are integrated results from UltIMMa-1 and -2. The open-label extension (OLE) data are a sub-analysis of LIMMitless and include only patients from UltIMMa-1 and -2 who completed the RCT and then enrolled in the OLE. LIMMitless is an OLE for which patients who completed either UltIMMa trial, IMMhance, or IMMvent were eligible to participate.<sup>4-7</sup>”

Source: [SKYRIZI: STELARA® to SKYRIZI® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-stelara#:~:text=The%20randomized%20controlled%20trial%20data,or%20IMMvent%20were%20eligible%20to)

> “LOCF=Last observation carried forward; OLE=Open-label extension; RCT=Randomized controlled trial.”

Source: [SKYRIZI: STELARA® to SKYRIZI® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-stelara#:~:text=LOCF%3DLast%20observation%20carried%20forward%3B%20OLE%3DOpen%2Dlabel%20extension%3B%20RCT%3DRandomized%20controlled%20trial.)

> “In an open-label extension, there is potential for enrichment of the long-term data in the remaining patient populations since patients who are unable to tolerate or do not respond to the drug often drop out.”

Source: [SKYRIZI: STELARA® to SKYRIZI® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-stelara#:~:text=In%20an%20open%2Dlabel%20extension%2C%20there,the%20drug%20often%20drop%20out.)

> “The ustekinumab used as a biologic active control in UltIMMa-1 and UltIMMa-2 was sourced from the European Union. Comparability between non–US-approved ustekinumab and US-approved ustekinumab has not been established.”

Source: [SKYRIZI: STELARA® to SKYRIZI® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-stelara#:~:text=The%20ustekinumab%20used%20as%20a,ustekinumab%20has%20not%20been%20established.)

Note: The 73% figure is in the section of the comparison page on patients switched from blinded ustekinumab to open-label Skyrizi; the page text gives no denominator, and the page gives the PASI 90 rate of these patients before the switch only in a chart. The 73% is a last-observation-carried-forward result in the open-label extension sub-analysis, which includes only patients who completed UltIMMa-1 or -2 and enrolled in LIMMitless. The switch data are not in the Prescribing Information; the page cites Strober et al., EADV 2019.

<a id="skyrizi-switch-from-humira"></a>

### Does switching to Skyrizi help Humira (adalimumab) patients who did not reach PASI 90?

Applies to: Adults with moderate-to-severe plaque psoriasis

> “In Part B, HUMIRA patients who achieved PASI 50 to <90 were re-randomized 1:1”

Source: [SKYRIZI: HUMIRA® to SKYRIZI® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-humira#:~:text=In%20Part%20B%2C%20HUMIRA%20patients,to%20%3C90%20were%20re%2Drandomized%201%3A1)

> “66% OF SKYRIZI PATIENTS ACHIEVED PASI 90 VS 21% OF HUMIRA PATIENTS (NRI)<sup>2</sup>
>
> WEEK 44 RESULTS (PART B)
>
> *p<0.0001”

Source: [SKYRIZI: HUMIRA® to SKYRIZI® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-humira#:~:text=66%25%20OF%20SKYRIZI%20PATIENTS%20ACHIEVED,%2Ap%3C0.0001)

> “PART B Primary Endpoint: PASI 90 at Week 44”

Source: [SKYRIZI: HUMIRA® to SKYRIZI® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-humira#:~:text=PART%20B%20Primary%20Endpoint%3A%20PASI%2090%20at%20Week%2044)

> “In Part A of the study, patients were randomized 1:1 to either SKYRIZI (150 mg) at Weeks 0 and 4, and every 12 weeks thereafter, or HUMIRA at an initial dose of 80 mg followed by 40 mg every other week starting 1 week after the initial dose. At Week 16, in Part B, patients taking HUMIRA with a PASI score of ≥50 but <90 were re-randomized 1:1 to either receive SKYRIZI (150 mg) at Weeks 16, 20, and 32, or continue HUMIRA. Patients who continued SKYRIZI in Part B remained on every-12-week dosing.<sup>3</sup>”

Source: [SKYRIZI: HUMIRA® to SKYRIZI® Switch Data - Plaque Psoriasis, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy/skyrizi-vs-humira#:~:text=In%20Part%20A%20of%20the%20study%2C%20patients%20were%20randomized%201%3A1,Part%20B%20remained%20on%20every%2D12%2Dweek)

Note: Part B included only Humira patients with PASI 50 to <90 at Week 16. IMMvent is not described in the Skyrizi Prescribing Information; the result is from the comparison page of the Skyrizi HCP site, which cites Reich et al., Lancet 2019. The page text gives no denominators for these rates.

## Dosing

<a id="skyrizi-body-weight"></a>

### Does the Skyrizi dose depend on body weight?

> “Risankizumab-rzaa clearance and volume of distribution increase and plasma concentrations 
> decrease as body weight increases; however, no dose adjustment is recommended based on body 
> weight in adult patients.”

Source: [SKYRIZI: Prescribing information, page 20, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=20)

> “Table 1. Recommended Dose of SKYRIZI for Pediatric Patients 6 Years of Age and Older 
> with Moderate-to-Severe Plaque Psoriasis 
> Body Weight  
> Recommended Dose 
> less than 40 kg 
> 55 mg 
> 40 kg or greater 
> 150 mg”

Source: [SKYRIZI: Prescribing information, page 4, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=4)

<a id="skyrizi-dosing-schedule"></a>

### What is the Skyrizi dosage for plaque psoriasis?

> “2.2 Recommended Dosage for Moderate-to-Severe Plaque Psoriasis 
> Adults 
> The recommended dosage for adults is 150 mg administered by subcutaneous injection at Week 
> 0, Week 4, and every 12 weeks thereafter [see Dosage and Administration (2.7)].  
> Pediatric Patients 6 Years of Age and Older 
> The recommended dosage for pediatric patients 6 years of age and older is based on body weight 
> (see Table 1) and administered by subcutaneous injection at Week 0, Week 4, and every 
> 12 weeks thereafter [see Dosage and Administration (2.7)].”

Source: [SKYRIZI: Prescribing information, page 3, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=3)

> “Table 1. Recommended Dose of SKYRIZI for Pediatric Patients 6 Years of Age and Older 
> with Moderate-to-Severe Plaque Psoriasis 
> Body Weight  
> Recommended Dose 
> less than 40 kg 
> 55 mg 
> 40 kg or greater 
> 150 mg”

Source: [SKYRIZI: Prescribing information, page 4, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=4)

> “4 doses per year after 2 initiation doses
> at Weeks 0 and 4 (150 mg/dose)<sup>1</sup>”

Source: [SKYRIZI: SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps), captured 2026-11-12](https://www.skyrizihcp.com/dermatology/psoriasis-efficacy#:~:text=4%20doses%20per%20year%20after,Weeks%200%20and%204%20%28150)

## Administration

<a id="skyrizi-how-to-inject"></a>

### How and where is Skyrizi injected?

> “• Do not inject into areas where the skin is tender, bruised, erythematous, indurated or affected 
> by any lesions. Appropriate sites for injection by the patient are: front of the thighs or the 
> abdomen at least 2 inches from the navel.”

Source: [SKYRIZI: Prescribing information, page 6, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=6)

> “Prefilled pens and prefilled syringes:”

Source: [SKYRIZI: Prescribing information, page 6, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=6)

> “• Remove from the refrigerator and allow to reach room temperature out of direct sunlight 
> (30 minutes to 90 minutes for the prefilled pen and 15 minutes to 30 minutes for the prefilled 
> syringe) without removing the prefilled pens or prefilled syringes from the carton.  
> • Administration in the upper, outer arm may only be performed by a healthcare professional 
> or caregiver.  
> • If the dose requires more than one injection: Inject in different locations at least 1 inch apart 
> (such as thighs or abdomen).”

Source: [SKYRIZI: Prescribing information, page 7, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=7)

<a id="skyrizi-self-injection"></a>

### Can patients inject Skyrizi themselves?

> “• Provide proper training to patients and/or caregivers on the subcutaneous injection technique 
> of SKYRIZI. After proper training: 
> Adults  
> o Adults may self-inject SKYRIZI. 
> Pediatric Patients 6 Years of Age and Older 
> o For pediatric patients 10 years of age and older, it is recommended that SKYRIZI be 
> administered by or under the supervision of an adult. 
> o For pediatric patients 6 to less than 10 years of age, SKYRIZI should be administered 
> by an adult.”

Source: [SKYRIZI: Prescribing information, page 6, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=6)

> “Instruct patients or caregivers to perform the first self-injected dose under the supervision and 
> guidance of a qualified healthcare professional for training in preparation and administration of 
> SKYRIZI, including choosing anatomical sites for administration, and proper subcutaneous 
> injection technique [see Dosage and Administration (2.7)].”

Source: [SKYRIZI: Prescribing information, page 43, captured 2026-11-12](https://www.skyrizihcp.com/prescribinginfo#page=43)

<a id="skyrizi-pen-vs-syringe"></a>

### Is the Skyrizi pen bioequivalent to the prefilled syringe?

> “*Bioequivalence was demonstrated between a single 150 mg/mL injection and two 75 mg/0.83 mL injections in a prefilled syringe.
> Bioequivalence was also demonstrated between 150 mg/mL prefilled syringe and prefilled pen.”

Source: [SKYRIZI: SKYRIZI® (risankizumab-rzaa) Injection Pen for Ps and PsA, captured 2026-11-12](https://www.skyrizihcp.com/dermatology/dosing/pso-psa-injection-device#:~:text=%2ABioequivalence%20was%20demonstrated%20between%20a,prefilled%20syringe%20and%20prefilled%20pen.)

## Related pages
- [Medical information: Skyrizi (risankizumab-rzaa): Plaque psoriasis](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/specific-populations)
- [Storage and supply](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/skyrizi--plaque-psoriasis/access-and-coverage)
